Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers
- 1 January 1999
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 36 (Supplement), 1-11
- https://doi.org/10.2165/00003088-199936001-00001
Abstract
Objective The objective of these studies was to examine the clinical pharmacokinetics and safety of zanamivir, an influenza A and B virus neuraminidase inhibitor, when administered to healthy...Keywords
This publication has 9 references indexed in Scilit:
- Safety and Efficacy of Intravenous Zanamivir in Preventing Experimental Human Influenza A Virus InfectionAntimicrobial Agents and Chemotherapy, 1999
- Safety and Efficacy of Once Daily Intranasal Zanamivir in Preventing Experimental Human Influenza a InfectionAntiviral Therapy, 1999
- Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.Clinical Pharmacokinetics, 1999
- Pharmacoscintigraphic Evaluation of Lung Deposition of Inhaled Zanamivir in Healthy VolunteersClinical Pharmacokinetics, 1999
- The Low Potential for Drug Interactions with ZanamivirClinical Pharmacokinetics, 1999
- Deposition and Disposition of [C]Zanamivir Following Administration as an Intranasal SprayClinical Pharmacokinetics, 1999
- Estimation of nasal epithelial lining fluid using urea as a markerJournal of Allergy and Clinical Immunology, 1993
- 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitroAntimicrobial Agents and Chemotherapy, 1993
- Rational design of potent sialidase-based inhibitors of influenza virus replicationNature, 1993